This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2010 Remove Business Model Remove Conflict of Interest Remove Ethics
article thumbnail

Big Pharma's Hidden Business Model and How Your Company Funds It

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. At Harvard's Edmond J.

Business Model 15
Business Model Company Pharmaceuticals Price 15
article thumbnail

How Pharma Can Fix Its Reputation and Its Business at the Same Time

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. One antidote to these problems is to transform “access to medicine” from a relentless activist slogan to a fully-fledged business strategy. Enhance corporate reputations.

Reputation 8
Reputation Pharmaceuticals Price Business Model 8
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 5,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024